Vacunas frente a SARS-CoV-2 y piel

Krammer, 2020, SARS-CoV-2 vaccines in development, Nature., 586, 516, 10.1038/s41586-020-2798-3 Boutron, 2020, The COVID-NMA Project: Building an evidence ecosystem for the COVID-19 pandemic, Ann Intern Med., 173, 1015, 10.7326/M20-5261 Rahimi, 2021, Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection, Genomics., 113, 1221, 10.1016/j.ygeno.2020.09.059 Galván Casas, 2020, Classification of the cutaneous manifestations of COVID-19: A rapid prospective nationwide consensus study in Spain with 375 cases, Br J Dermatol., 183, 71, 10.1111/bjd.19163 Kantor, 2021, May 2021: Heterogeneity in reported skin manifestations of COVID-19 and vaccines, J Am Acad Dermatol., 84, 1251, 10.1016/j.jaad.2021.03.022 Dong, 2020, A systematic review of SARS-CoV-2 vaccine candidates, Signal Transduct Target Ther., 5, 237, 10.1038/s41392-020-00352-y Pollet, 2021, Recombinant protein vaccines, a proven approach against coronavirus pandemics, Adv Drug Deliv Rev., 170, 71, 10.1016/j.addr.2021.01.001 Hervé, 2019, The how's and what's of vaccine reactogenicity, Npj Vaccines., 4, 39, 10.1038/s41541-019-0132-6 EMA European Medicines Agency. Vaxzevria (previously COVID-19 Vaccine AstraZeneca). [Consultado 01 Abr 2021]. Disponible en: https://www.ema.europa.eu/en/medicines/human/EPAR/vaxzevria-previously-covid-19-vaccine-astrazeneca EMA European Medicines Agency. EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU. [Consultado 01 Abr 2021].Disponible en: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-janssen-authorisation-eu Polack, 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med., 383, 2603, 10.1056/NEJMoa2034577 Baden, 2021, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med., 384, 403, 10.1056/NEJMoa2035389 Recher, 2018, Immune system correlates of extensive limb swelling in response to conjugated pneumococcal vaccination, Npj Vaccines., 3, 17, 10.1038/s41541-018-0059-3 Pitlick, 2021, Polyethylene glycol and polysorbate skin testing in the evaluation of COVID-19 vaccine reactions: Early report, Ann Allergy Asthma Immunol., 126, 735, 10.1016/j.anai.2021.03.012 Wei, 2021, “COVID arm”: A reaction to the Moderna vaccine, JAAD Case Rep., 10, 92, 10.1016/j.jdcr.2021.02.014 Blumenthal, 2021, Delayed large local reactions to mRNA-1273 vaccine against SARS-CoV-2, N Engl J Med., 384, 1273, 10.1056/NEJMc2102131 Fernandez-Nieto, 2021, Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. «COVID-arm»: A clinical and histological characterization, J Eur Acad Dermatol Venereol., 10.1111/jdv.17250 Humphrey, 2020, Retrospective review of delayed adverse events secondary to treatment with a smooth, cohesive 20-mg/mL hyaluronic acid filler in 4500 patients, J Am Acad Dermatol., 83, 86, 10.1016/j.jaad.2020.01.066 Rowland-Warmann, 2021, Hypersensitivity reaction to hyaluronic acid dermal filler following novel Coronavirus infection – a case report, J Cosmet Dermatol., 10.1111/jocd.14074 Munavalli, 2021, COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to hyaluronic acid dermal fillers: A challenging clinical conundrum in diagnosis and treatment, Arch Dermatol Res, 1 Munavalli, 2021, Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II–induced cutaneous inflammation, JAAD Case Rep., 10, 63, 10.1016/j.jdcr.2021.02.018 Ackerman, 2021, Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine, J Eur Acad Dermatol Venereol., 10.1111/jdv.17248 Burlando, 2021, COVID-19 «second wave» and vaccines: The dermatologists’ perspective, Int J Dermatol., 10.1111/ijd.15547 Hiltun, 2021, Lichen planus arising after COVID-19 vaccination, J Eur Acad Dermatol Venereol., 10.1111/jdv.17221 Gambichler, 2021, Prompt onset of erythema multiforme following the first BNT162b2 SARS-CoV-2 vaccination, J Eur Acad Dermatol Venereol., 10.1111/jdv.17225 Bostan, 2021, Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?, J Cosmet Dermatol., 10.1111/jocd.14035 McMahon, 2021, Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases, J Am Acad Dermatol., 10.1016/j.jaad.2021.03.092 Fernández-Prada, 2021, Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain. January and February 2021, Eurosurveillance., 26, 10.2807/1560-7917.ES.2021.26.10.2100193 Shimabukuro, 2021, Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US—December 14, 2020-January 18, 2021, JAMA., 325, 1101, 10.1001/jama.2021.1967 Corbeddu, 2021, Transient cutaneous manifestations after administration of Pfizer-BioNTech COVID-19 Vaccine: An Italian single-centre case series, J Eur Acad Dermatol Venereol., 10.1111/jdv.17268 Ring, 2021, Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases – practical recommendations. A position statement of ETFAD with external experts, J Eur Acad Dermatol Venereol., 10.1111/jdv.17237 Iavarone, 2017, Mechanism of action of mRNA-based vaccines, Expert Rev Vaccines., 16, 871, 10.1080/14760584.2017.1355245 Zhang, 2019, Advances in mRNA vaccines for infectious diseases, Front Immunol., 10, 594, 10.3389/fimmu.2019.00594